Phase 2 N=21 Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
Dystonia
Primary: Physician Global Perception of Change - Blinded Rater 1 — 1; 1; 1; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=267 RISE Adult Medication Study
Prediabetes · Type 2 Diabetes
Primary: ß-cell Response Measured by Hyperglycemic Clamp — 3.65; 3.58; 3.60; 3.73 nmol/L — p=>0.05
Phase 2 N=38 Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Phase 3 N=286 Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Geographic Atrophy · Dry Age-Related Macular Degeneration
Primary: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence — 0.292; 0.402; 0.321; 0.444 millimeters (mm) — p=0.0072
Phase 2 N=44 Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
Diabetic Macular Edema
Primary: Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8 — 22; 22; 22; 22 Participants
Phase 4 N=20 The Invia Motion at Cesarean Study
Negative Pressure Wound Therapy · Cesarean Section; Infection
Primary: Pain Scores: Discharge Time Frame — 2.5 score on a scale
Phase 3 N=187 Low-Dose Atropine for Treatment of Myopia
Myopia
Primary: Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. — 0; 0; 1; 0 Participants
N/A N=30 Enhancing Cognitive Control in Mild Cognitive Impairment Via Non-invasive Brain Stimulation
Mild Cognitive Impairment
Primary: Divided Attention Performance — 9.29; 9.31 difficulty level acheived
N/A N=28 Novel MRI Sequence MR Fingerprinting in Breast MRI Feasibility Study
Breast Screening
Primary: Ratio of Intensity Score of Normal Breast Tissue for Left Breast Tissue Compared to Right for T1 Imaging Sequence — 1.07 ratio
Phase 4 N=36 Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients
Kidney Transplant
Primary: Time to First Therapeutic Tacrolimus Trough Concentration From Initiation of Tacrolimus Extended Release Measured in Days — 4.5; 6; 13.5 days
Phase 3 N=691 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
Glioblastoma · Gliosarcoma
Primary: Overall Survival (OS) — 18.7; 18.9 months — p=0.633
N/A N=39 Time-restricted Eating in Cancer Survivorship: A Single-arm Feasibility Pilot Study
Cancer Survivorship
Primary: Mean Percent of Days That Participants Adhere to the TRE Dietary Pattern — 90.1 percent of days
N/A N=19 Studying the Effects of Natural Visual Scene Changes on Typical Adult Visual Perception
Visual Perception
Primary: Psychophysical Measurements of Horizontal Discrimination Threshold — .30962; .35002; .32849 degrees of visual angle — p=.024356
Phase 3 N=19 RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
Venous Thromboembolism · Menstruation
Primary: PBAC Scores — 292; 146 score on a scale
Phase 2 N=312 Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
Hypercholesterolemia · Heterozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) to Day 180 — 9.0; -47.6; -51.9; -56.3 percent change in LDL-C — p=<.0001